Clinical trials
Total Neoadjuvant Therapy clinical trials
Below are recruiting total neoadjuvant therapy clinical trials, each written for real people, not researchers. We’re tracking 174 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06925243RecruitingPhase 3
Apatinib, Sintilimab, and Chemo for Intestinal Gastric Cancer
This phase 3 trial tests adding the targeted drug apatinib to a standard combination of sintilimab (immunotherapy) and chemotherapy (SOX regimen) given before surgery for a specific type of stomach or gastroesophageal junction cancer (intestinal type, HER2-negative). The goal is to see if the three-drug combination works better than the two-drug combination in shrinking the tumor and improving outcomes before surgery.
Lanzhou, GansuAges 18–75 - NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT07286253RecruitingPhase 2
QL1706 plus chemo before surgery for advanced cervical cancer
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
Guangzhou, GuangdongAges 18–70 - NCT07695259RecruitingPhase 4
Olaparib with trastuzumab and pertuzumab for older women with HER2+ breast cancer
This study tests a combination of two antibody drugs (trastuzumab and pertuzumab) plus a targeted pill (olaparib) given before surgery to treat elderly women with HER2-positive breast cancer. The goal is to see if this approach helps shrink tumors or eliminate them entirely before surgery.
Hangzhou, ZhejiangAges 60 years+ - NCT06617936RecruitingPhase 2
Immunotherapy plus endostatin and chemo for stage III lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Jinan, ShandongAges 18–75 - NCT06834126RecruitingPhase 1
Papaverine with radiation for advanced rectal cancer
This trial tests if adding papaverine (a drug) to radiation therapy can help people with locally advanced rectal cancer avoid surgery and keep their rectum. It is for patients who have already had chemotherapy and want a non-surgical approach.
Duarte, CaliforniaAges 18 years+ - NCT06209294RecruitingPhase 2
New drug combo before fertility-sparing surgery for cervical cancer
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT06664996RecruitingPhase 2
Immunotherapy plus radiation before surgery for liver cancer with portal vein tumor clot
This trial tests combining an immunotherapy drug (sintilimab) with focused radiation (SBRT) before surgery for liver cancer that has spread into a branch of the portal vein. The goal is to see if this combination can shrink the tumor and make surgery more successful.
Chengdu, SichuanAges 18 years+ - NCT05837806RecruitingPhase 2
Tislelizumab and disitamab as pre-surgery treatment for HER2 UTUC
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
TianjinAges 18 years+ - NCT07033819RecruitingPhase 2
Fuzuloparib and apatinib before surgery for ovarian cancer
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
Beijing, Beijing MunicipalityAges 18–70 - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75 - NCT06761287Recruiting
Choosing surgery after chemo for advanced rectal cancer
This study looks at patients with advanced rectal cancer who had treatment (chemotherapy or radiation) before surgery. They want to see if it's safe to avoid surgery in those who had a good response to initial treatment.
BrusselsAges 18 years+ - NCT07130240RecruitingPhase 2
Ivonescimab with chemo before surgery for cervical cancer
This trial tests adding a new drug called Ivonescimab to standard chemotherapy (paclitaxel and cisplatin) given before a hysterectomy in women with cervical cancer stage IB2 or IIA1 (tumor size 2-4 cm). The goal is to see if this combination improves outcomes compared to chemo alone.
ShanghaiAges 18–75 - NCT07126119RecruitingPhase 2
Immunotherapy plus chemo before surgery for upper tract cancer
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
Tianjin, Outside U.S.Ages 18 years+ - NCT07125547RecruitingPhase 2
Immunotherapy and chemo before surgery for ureteral cancer
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (nab-paclitaxel) given before surgery for ureteral cancer. The goal is to see if the treatment shrinks the tumor and makes the surgery more effective.
Tianjin, Outside U.S.Ages 18 years+ - NCT05947838Recruiting
Blood test helps choose chemotherapy before colorectal or appendix surgery
This study uses a blood test called ctDNA to help tailor (personalize) neoadjuvant chemotherapy for people with colorectal or appendix cancer before surgery. The goal is to see if using ctDNA can help doctors pick the most appropriate chemotherapy plan for you.
Houston, TexasAges 18 years+ - NCT06341595RecruitingPhase 2
Chemo, radiation and immunotherapy before surgery for stomach cancer with PALM
This trial tests combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) before surgery for advanced stomach cancer that has spread to lymph nodes near the aorta (called PALM). The goal is to see if this approach can shrink the tumor enough to allow complete removal.
Nanjing, JiangsuAges 18–75 - NCT07458529RecruitingPhase 2
Chemoradiation plus immunotherapy with or without probiotics for rectal cancer
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07059299RecruitingPhase 1
Immunotherapy plus chemo before stomach/esophagus cancer surgery
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
FrankfurtAges 18 years+ - NCT07369882Recruiting
Less extensive surgery after immunotherapy for advanced head and neck cancer
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07789210RecruitingPhase 2
Neoadjuvant targeted therapy for BRAF-mutant colorectal cancer
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07876154RecruitingPhase 2
Immunotherapy plus chemo before surgery for locally advanced cervical cancer
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
Xi'an, ShaanxiAges 18–70 - NCT05429463RecruitingPhase 3
Surgery-ready lung cancer treatment with immunotherapy plus chemo
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hangzhou, ZhejiangAges 18–75 - NCT05941338RecruitingPhase 2
Tirelizumab plus chemotherapy before head and neck surgery
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
Guangzhou, GuangdongAges 18–65
Hear when a new Total Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for total neoadjuvant therapy?
- Yes. Clin2 currently lists 174 recruiting total neoadjuvant therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a total neoadjuvant therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a total neoadjuvant therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.